Journal article · 2026 · Open access

Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial

Hermann Einsele, J. San‐Miguel, Binod Dhakal, Cyrille Touzeau, Xavier P Leleu, Niels W.C.J. van de Donk, Surbhi Sidana, Albert Oriol, Yael Chava Cohen, Simon James Harrison, María‐Victoria Mateos, Martínez-López Joaquín and 19 more

The Lancet Oncology, 27(2), 254–268 · Published 7 January 2026 · DOI 10.1016/s1470-2045(25)00653-9

Open full textCite this paper

In brief

“Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial” is a 2026 journal article by Hermann Einsele and 30 co-authors, published in The Lancet Oncology. OpenAlex counts 69 citations as of 17 November 2026, which puts it in the top 1% of works published in 2026 by citations. It is open access under a CC BY licence: the full text is free to read at The Lancet Oncology.

Citations
69
Most cited in
2026 (69)
Field-weighted impact
237.74
References
28
Authors
31

Abstract

Background In CARTITUDE-4, a single infusion of ciltacabtagene autoleucel (cilta-cel) significantly prolonged progression-free survival in patients with lenalidomide-refractory multiple myeloma. We report updated overall survival and longer-term efficacy and safety outcomes. Methods CARTITUDE-4 is an open-label, multicentre, randomised, phase 3 trial at 81 hospital sites in the USA, Europe, Asia, and Australia. Eligible patients were adults (aged >18 years) with lenalidomide-refractory multiple myeloma, with one to three previous treatment lines, including a proteasome inhibitor and an immunomodulatory drug, and an Eastern Cooperative Oncology Group performance status of 0 or 1. After the trial started, the threshold defining measurable disease was lowered to 0·5 g/dL from 1·0 g/dL serum monoclonal paraprotein on July 2, 2021, to increase trial access. Patients were randomly assigned (1:1) via a computerised algorithm and balanced with permuted blocks, with stratification by physician's choice of pomalidomide–bortezomib–dexamethasone versus daratumumab–pomalidomide–dexamethasone, International Staging System stage, and number of previous treatment lines. Patients were assigned to cilta-cel (apheresis, bridging therapy [at least one pomalidomide–bortezomib–dexamethasone or daratumumab–pomalidomide–dexamethasone cycle], lymphodepletion, then cilta-cel infusion [0·75 × 10 6 CAR T cells per kg]) or standard of care (pomalidomide–bortezomib–dexamethasone [21-day cycles: 4 mg/day oral pomalidomide on days 1–14; 1·3 mg/m 2 subcutaneous bortezomib twice a week for 2 weeks for eight cycles, then once a week for 2 weeks per cycle; 20 mg or, if aged >75 years, 10 mg oral dexamethasone on days 1, 2, 4, 5, 8, 9, 11, and 12 for eight cycles, then days 1, 2, 8, and 9 per cycle] or daratumumab–pomalidomide–dexamethasone [28-day cycles: 1800 mg subcutaneous daratumumab weekly for 2 cycles, every 2 weeks for four cycles, then every 4 weeks; 4 mg/day oral pomalidomide on days 1–21; 40 mg/week or, if aged >75 years, 20 mg/week oral or intravenous dexamethasone]). The primary endpoint was progression-free survival, previously published. In this Article, we report a prespecified second interim analysis of overall survival and an updated analysis of progression-free survival in the intention-to-treat population. This trial was registered at ClinicalTrials.gov (NCT04181827) and is ongoing. Findings Patients were randomly assigned between July 10, 2020, and Nov 17, 2021, to receive cilta-cel (n=208) or standard of care (n=211). At a median follow-up of 33·6 months (IQR 20·3–35·0), median progression-free survival was not reached (95% CI 34·5 months–not evaluable) in the cilta-cel group versus 11·8 months (9·7–14·0) in the standard-of-care group (HR 0·29 [95% CI 0·22–0·39]). Median overall survival was not reached (95% CI not evaluable) with cilta-cel versus not reached (37·7 months–not evaluable) with standard of care (HR 0·55 [95% CI 0·39–0·79]…

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Einsele, H., San‐Miguel, J., Dhakal, B., Touzeau, C., Leleu, X. P., van de Donk, N. W., Sidana, S., Oriol, A., Cohen, Y. C., Harrison, S. J., Mateos, M., Joaquín, M.-L., Corradini, P., Karlin, L., Chen, D., Li, Q., Yeh, T.-M., Li, K., Plaks, V., . . . Popat, R. (2026). Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology, 27(2), 254–268. https://doi.org/10.1016/s1470-2045(25)00653-9

MLA 9

Einsele, Hermann, et al. “Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.” The Lancet Oncology, vol. 27, no. 2, 2026, pp. 254–268. https://doi.org/10.1016/s1470-2045(25)00653-9.

Chicago

Einsele, Hermann, J. San‐Miguel, Binod Dhakal, Cyrille Touzeau, Xavier P Leleu, Niels W.C.J. van de Donk, Surbhi Sidana, et al. 2026. “Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial.” The Lancet Oncology 27 (2): 254–268. https://doi.org/10.1016/s1470-2045(25)00653-9.

Harvard

Einsele, H. et al. (2026) ‘Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial’, The Lancet Oncology, 27(2), pp. 254–268. doi:10.1016/s1470-2045(25)00653-9.

IEEE

H. Einsele et al., “Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial,” The Lancet Oncology, vol. 27, no. 2, pp. 254–268, 2026, doi: 10.1016/s1470-2045(25)00653-9.

BibTeX

@article{einsele2026cilta,
  title     = {{Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial}},
  author    = {Einsele, Hermann and San‐Miguel, J. and Dhakal, Binod and Touzeau, Cyrille and Leleu, Xavier P and van de Donk, Niels W.C.J. and Sidana, Surbhi and Oriol, Albert and Cohen, Yael Chava and Harrison, Simon James and Mateos, María‐Victoria and Joaquín, Martínez-López and Corradini, Paolo and Karlin, Lionel and Chen, Diana and Li, Quanlin and Yeh, Tzu-min and Li, Katherine and Plaks, Vicki and Slaughter, Ana and Lonardi, Carolina and Benachour, Nina and Ghosh, Arnab and Vogel, Martin and Schecter, Jordan Mark and Lendvai, Nikoletta K. and Koneru, Mythili and Patel, Nitin and Florendo, Erika and Ho, Phoebe Joy and others},
  journal   = {The Lancet Oncology},
  year      = {2026},
  volume    = {27},
  number    = {2},
  pages     = {254--268},
  doi       = {10.1016/s1470-2045(25)00653-9},
  url       = {https://doi.org/10.1016/s1470-2045(25)00653-9}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments

  • ciltacabtagene autoleucel
  • CAR T-cell therapy
  • lenalidomide-refractory multiple myeloma
  • overall survival
  • progression-free survival
  • lymphocyte depletion

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Einsele, H., San‐Miguel, J., Dhakal, B., Touzeau, C., Leleu, X. P., van de Donk, N. W., Sidana, S., Oriol, A., Cohen, Y. C., Harrison, S. J., Mateos, M., Joaquín, M.-L., Corradini, P., Karlin, L., Chen, D., Li, Q., Yeh, T.-M., Li, K., Plaks, V., . . . Popat, R. (2026). Cilta-cel in lenalidomide-refractory multiple myeloma (CARTITUDE-4): an updated analysis including overall survival from an open-label, multicentre, randomised, phase 3 trial. The Lancet Oncology, 27(2), 254–268. https://doi.org/10.1016/s1470-2045(25)00653-9

How many times has this paper been cited?

69 times, according to OpenAlex on 17 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at The Lancet Oncology: sign in and open the full text from this page.

Who wrote this paper?

Hermann Einsele, J. San‐Miguel, Binod Dhakal, Cyrille Touzeau, Xavier P Leleu, Niels W.C.J. van de Donk, Surbhi Sidana, Albert Oriol, Yael Chava Cohen, Simon James Harrison, María‐Victoria Mateos, Martínez-López Joaquín and 19 more.

What is the DOI of this paper?

10.1016/s1470-2045(25)00653-9, permanently at https://doi.org/10.1016/s1470-2045(25)00653-9. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 17 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.